In spite of their significant differences in clinical manifestation and pathologic appearance, the most common entities of PTCL, including AITL, PTCL-NOS and ALCL (ALK positive and negative), tend to be treated similarly [34]. This evidence concerns the gene ALK and mature T-cell and NK-cell non-Hodgkin lymphoma.